Harrow (HROW) to Release Quarterly Earnings on Thursday

Harrow (NASDAQ:HROW) will likely be announcing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Harrow to post earnings of $0.40 per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 8:00 AM ET.

Harrow Price Performance

Harrow stock opened at $34.48 on Thursday. Harrow has a 12-month low of $20.85 and a 12-month high of $54.85. The stock has a market cap of $1.28 billion, a P/E ratio of -202.81 and a beta of 0.05. The company has a 50-day moving average price of $45.14 and a 200 day moving average price of $43.55. The company has a current ratio of 2.20, a quick ratio of 2.06 and a debt-to-equity ratio of 4.67.

Institutional Trading of Harrow

Institutional investors have recently added to or reduced their stakes in the stock. Campbell & CO Investment Adviser LLC acquired a new position in Harrow during the fourth quarter worth $596,000. Ameriprise Financial Inc. acquired a new stake in shares of Harrow in the third quarter valued at $507,000. The Manufacturers Life Insurance Company raised its holdings in shares of Harrow by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock valued at $505,000 after buying an additional 341 shares during the period. Corsair Capital Management L.P. purchased a new stake in shares of Harrow in the 4th quarter valued at $490,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Harrow by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock worth $483,000 after acquiring an additional 790 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Wall Street Analysts Forecast Growth

HROW has been the subject of a number of recent analyst reports. BTIG Research restated a “buy” rating and set a $63.00 price target on shares of Harrow in a report on Wednesday. Zacks Research lowered Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 3rd. Cantor Fitzgerald cut their target price on Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. HC Wainwright lifted their target price on Harrow from $69.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Finally, William Blair reaffirmed an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Harrow currently has an average rating of “Moderate Buy” and a consensus price target of $71.14.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.